British NICE Guide recommends Merck's anti-cholesterol drug Ezetrol
British NICE Guide recommends Merck's anti-cholesterol drug Ezetrol October 23, 2015 Source: Bio Valley NICE recommends that patients with primary hypercholesterolemia (familial heterozygous or non-familial) who cannot take statins take Ezetrol (ezetimibe), which mainly meets the needs of three types of patients: one wants to control the blood lipid concentration, thus preliminary Prevention of cardiovascular disease caused by dyslipidemia; second, for people with type 2 diabetes who have a high risk of cardiovascular disease in the next 10 years, and finally for those who need to control blood lipids for cardiovascular disease Level prevention patients. Primary heterozygous familial hypercholesterolemia is a type of genetically deficient disease with approximately 120,000 patients in the UK. Non-familial hypercholesterolemia is related to hereditary traits and to lifestyle, smoking, lack of exercise and other lifestyle habits, affecting the health of about 2 million people. Whether it is familial or non-familial hypercholesterolemia, patients have a high risk of developing cardiovascular disease, which is the leading cause of death. Ezetrol is an intestinal cholesterol absorption inhibitor that blocks intestinal absorption, bile-derived cholesterol, and phytosterols, but does not affect intestinal absorption of triglycerides or fat-soluble vitamins. This means that Ezetrol can be combined with statins as a combination or alternative to cholesterol reduction. NICE's drafting guidelines are different from the ones released in 2007. It reflects the fact that current clinical practice should focus more on controlling the risk of cardiovascular disease than just lowering cholesterol levels. Early NICE guidelines focused on reducing cholesterol, and the main difference in this updated guide is the emphasis on primary and secondary prevention of heart disease. The NICE committee believes that the optimal incremental cost-effectiveness for people in need of primary prevention of cardiovascular disease is that the cost of taking Ezetrol is at least £3,1900 per quality-adjusted life year compared to no treatment; The cost of taking statins and Ezetrol at the same time is at least £76,000/mass adjusted life year compared to taking statin alone. For people who need secondary prevention of cardiovascular disease, the optimal incremental cost-effectiveness is that the cost of using Ezetrol alone is at least £20,300/weight-adjusted compared to patients with type 2 diabetes who do not take any treatment. Year; compared to taking statin alone, the cost of taking Ezetrol at the same time is at least £76,000/mass adjusted life year. Safe Box,Small Safe Box,Safe Box For Money,Safe Box For Documents Ningbo Zhaomu Electronic Commerce Co., Ltd. , https://www.bofonhome.com